

Serena Pillozzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1850454/publications.pdf>

Version: 2024-02-01

88
papers

2,635
citations

201674

27
h-index

206112

48
g-index

89
all docs

89
docs citations

89
times ranked

3092
citing authors

#	ARTICLE	IF	CITATIONS
1	Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. , 2022, 237, 108170.		9
2	Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications, 2022, 32, 100603.	1.7	6
3	Chip-Based and Wearable Tools for Isothermal Amplification and Electrochemical Analysis of Nucleic Acids. Chemosensors, 2022, 10, 278.	3.6	6
4	Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 860.	3.7	37
5	Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers, 2021, 13, 1091.	3.7	21
6	Electrochemical and PEC platforms for miRNA and other epigenetic markers of cancer diseases: Recent updates. Electrochemistry Communications, 2021, 124, 106929.	4.7	23
7	Transgenic mice overexpressing the LH receptor in the female reproductive system spontaneously develop endometrial tumour masses. Scientific Reports, 2021, 11, 8847.	3.3	12
8	A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics, 2021, 11, 804.	2.6	5
9	Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles. BioMetals, 2021, 34, 867-879.	4.1	13
10	Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. British Journal of Cancer, 2021, 125, 94-100.	6.4	23
11	Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Current Oncology, 2021, 28, 1761-1772.	2.2	5
12	Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. Cancers, 2021, 13, 3044.	3.7	20
13	Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. Cancers, 2021, 13, 3863.	3.7	6
14	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno, 2021, 1, 253-263.	1.5	11
15	Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study. Current Oncology, 2021, 28, 3259-3267.	2.2	18
16	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules, 2021, 26, 5789.	3.8	23
17	Circulating miRNome profiling data in Behçet's syndrome. Data in Brief, 2021, 38, 107435.	1.0	3
18	Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?. Anti-Cancer Drugs, 2020, 31, 1091-1095.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma. <i>Anti-Cancer Drugs</i> , 2020, 31, 880-883.	1.4	1
20	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4691.	4.1	40
21	Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value?. <i>Reproductive Sciences</i> , 2020, 27, 592-598.	2.5	6
22	Somatostatin analogs in pregnant patients with neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2020, 31, 1096-1098.	1.4	5
23	ROS1 rearrangements are uncommon in biliary tract cancers. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	0
24	Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. <i>BioMetals</i> , 2019, 32, 939-948.	4.1	12
25	Data describing the effects of the Macrolide Antibiotic Clarithromycin on preclinical mouse models of Colorectal Cancer. <i>Data in Brief</i> , 2019, 26, 104406.	1.0	2
26	The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma. <i>Scientific Reports</i> , 2019, 9, 8586.	3.3	20
27	Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 656-660.	2.8	64
28	Engineering <sc>l</sc>-asparaginase for spontaneous formation of calcium phosphate bioinspired microreactors. <i>Physical Chemistry Chemical Physics</i> , 2018, 20, 12719-12726.	2.8	9
29	The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. <i>British Journal of Cancer</i> , 2018, 118, 200-212.	6.4	58
30	Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer. <i>Oncology Reports</i> , 2018, 41, 1560-1574.	2.6	11
31	Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrowâ€induced chemoresistance in acute leukemias. <i>Oncology Reports</i> , 2018, 41, 312-324.	2.6	12
32	Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients. <i>BioMed Research International</i> , 2018, 2018, 1-6.	1.9	6
33	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. <i>Inorganica Chimica Acta</i> , 2018, 470, 318-324.	2.4	8
34	Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. <i>Oncotarget</i> , 2018, 9, 10561-10571.	1.8	7
35	Pt₂(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. <i>Dalton Transactions</i> , 2017, 46, 3311-3317.	3.3	35
36	The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. <i>Science Signaling</i> , 2017, 10, .	3.6	49

#	ARTICLE	IF	CITATIONS
37	Circulating Endothelial Progenitor Cells in Type 1 Diabetic Patients: Relation with Patients' Age and Disease Duration. <i>Frontiers in Endocrinology</i> , 2017, 8, 278.	3.5	12
38	LH/hCG-Receptor Expression May Have a Negative Prognostic Value in Low-Risk Endometrial Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 190.	2.8	3
39	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2016, 163, 318-322.	3.5	5
40	Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels. <i>Blood Cancer Journal</i> , 2016, 6, e423-e423.	6.2	11
41	Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles. <i>BioMetals</i> , 2016, 29, 535-542.	4.1	13
42	Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. <i>Journal of Inorganic Biochemistry</i> , 2016, 165, 1-6.	3.5	26
43	New gold carbene complexes as candidate anticancer agents. <i>BioMetals</i> , 2016, 29, 905-911.	4.1	29
44	Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA = 1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. <i>Journal of Inorganic Biochemistry</i> , 2016, 160, 180-188.	3.5	23
45	Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel. <i>Blood</i> , 2016, 128, 3953-3953.	1.4	1
46	Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug. <i>Scientific Reports</i> , 2015, 5, 17736.	3.3	38
47	New Pyrimido-Indole Compound CD-160130 Preferentially Inhibits the K _v 11.1B Isoform and Produces Antileukemic Effects without Cardiotoxicity. <i>Molecular Pharmacology</i> , 2015, 87, 183-196.	2.3	26
48	cis-Pt I ₂ (NH ₃) ₂ : a reappraisal. <i>Dalton Transactions</i> , 2015, 44, 14896-14905.	3.3	45
49	Design, synthesis and characterisation of new chimeric ruthenium(II) "gold" complexes as improved cytotoxic agents. <i>Dalton Transactions</i> , 2015, 44, 11067-11076.	3.3	52
50	Hypoxia Increases Repopulating Ability of Myelodysplastic Syndrome Bone Marrow Cells. <i>Blood</i> , 2015, 126, 4753-4753.	1.4	0
51	Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups. <i>Leukemia</i> , 2014, 28, 1352-1355.	7.2	18
52	Searching for protein binding sites from Molecular Dynamics simulations and paramagnetic fragment-based NMR studies. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 561-566.	2.3	17
53	hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications. <i>Clinical Cancer Research</i> , 2014, 20, 1502-1512.	7.0	54
54	NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. <i>Dalton Transactions</i> , 2014, 43, 12150-12155.	3.3	34

#	ARTICLE	IF	CITATIONS
55	Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. <i>British Journal of Cancer</i> , 2014, 111, 1159-1167.	6.4	55
56	Over-Expression of the LH Receptor Increases Distant Metastases in an Endometrial Cancer Mouse Model. <i>Frontiers in Oncology</i> , 2013, 3, 285.	2.8	11
57	hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. <i>Scientific Reports</i> , 2013, 3, 3308.	3.3	75
58	Drug-induced glutamine depletion hinders the growth of β -catenin mutated human liver cancer xenografts. <i>FASEB Journal</i> , 2013, 27, 387.9.	0.5	0
59	Targeting Ion Channels in Leukemias: A New Challenge for Treatment. <i>Current Medicinal Chemistry</i> , 2012, 19, 683-696.	2.4	54
60	Deregulation of Ion Channel and Transporter Encoding Genes in Pediatric Gliomas. <i>Frontiers in Oncology</i> , 2012, 2, 53.	2.8	7
61	Ion Channels in Hematopoietic and Mesenchymal Stem Cells. <i>Stem Cells International</i> , 2012, 2012, 1-9.	2.5	33
62	Role of the Ether-a-go-go-Related Gene 1B Isoform in Hematopoiesis. <i>Blood</i> , 2012, 120, 1222-1222.	1.4	0
63	Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias. <i>Blood</i> , 2012, 120, 1506-1506.	1.4	0
64	Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. <i>Blood</i> , 2011, 117, 902-914.	1.4	119
65	Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up-regulation of hERG1 channels and of the VEGF-A pathway. <i>BMC Cancer</i> , 2010, 10, 504.	2.6	17
66	New Insights into the Regulation of Ion Channels by Integrins. <i>International Review of Cell and Molecular Biology</i> , 2010, 279, 135-190.	3.2	38
67	Physical and Functional Interaction between Integrins and hERG1 Channels in Cancer Cells. <i>Advances in Experimental Medicine and Biology</i> , 2010, 674, 55-67.	1.6	40
68	Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy. <i>Current Medicinal Chemistry</i> , 2009, 16, 66-93.	2.4	269
69	Overcoming Chemotherapy Resistance in Childhood Acute Lymphoblastic Leukemia by Targeting Ion Channels. <i>Blood</i> , 2009, 114, 3085-3085.	1.4	1
70	hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer. <i>Gynecologic Oncology</i> , 2008, 111, 496-501.	1.4	25
71	Identification of a Posttranslational Mechanism for the Regulation of hERG1 Channel Expression and hERG1 Current Density in Tumor Cells. <i>Molecular and Cellular Biology</i> , 2008, 28, 5043-5060.	2.3	54
72	The Increase of Endothelial Progenitor Cells in the Peripheral Blood: A New Parameter for Detecting Onset and Severity of Sepsis. <i>International Journal of Immunopathology and Pharmacology</i> , 2008, 21, 697-705.	2.1	43

#	ARTICLE	IF	CITATIONS
73	Potassium Channels as Novel Pharmacological Targets in Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 4034-4034.	1.4	1
74	A Macromolecular Signaling Complex Formed by CXCR4, VLA4 and hERG1 K ⁺ Channels Mediates Bone Marrow-Induced Chemo-Resistance in Childhood Acute Lymphoblastic Leukemias: Shortcoming Effects of hERG1 Channels Inhibitors.. <i>Blood</i> , 2008, 112, 1629-1629.	1.4	0
75	Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. <i>Journal of Biological Chemistry</i> , 2007, 282, 29384-29393.	3.4	17
76	VEGFR-1 (FLT-1), α 2 β 1 integrin, and hERG K ⁺ channel form a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. <i>Blood</i> , 2007, 110, 1238-1250.	1.4	165
77	Insights into the Structure/Function of Hepatocyte Growth Factor/Scatter Factor from Studies with Individual Domains. <i>Journal of Molecular Biology</i> , 2007, 367, 395-408.	4.2	80
78	Expression and Role of hERG1 Channels in Pediatric Acute Lymphoblastic Leukemias: Shortcoming of Drug Resistance by hERG1 Channel Inhibitors in Stoma-Supported Leukaemia Cell Cultures In Vitro.. <i>Blood</i> , 2007, 110, 724-724.	1.4	2
79	Treatment with hERG1 K ⁺ Channel Inhibitors Reduces Acute Myeloid Leukemia Cell Lines Engraftment into Nonobese Diabetic/Severe Combined Immunodeficient Mice and Prolongs Survival of Injected Mice.. <i>Blood</i> , 2007, 110, 877-877.	1.4	2
80	VEGFR-1 (FLT-1), β 1 Integrin and hERG K ⁺ Channel Form a Macromolecular Signaling Complex in Acute Myeloid Leukemia Cells.. <i>Blood</i> , 2006, 108, 2366-2366.	1.4	22
81	Human ether-a-go-go-related Gene 1 Channels Are Physically Linked to α 2 β 1 Integrins and Modulate Adhesion-dependent Signaling. <i>Molecular Biology of the Cell</i> , 2005, 16, 2972-2983.	2.1	147
82	c-Met Oncogene Enhances Fas-Mediated Apoptosis in B-ALL t(12;21) Cells.. <i>Blood</i> , 2005, 106, 858-858.	1.4	1
83	Physical and functional interaction between integrins and hERG potassium channels. <i>Biochemical Society Transactions</i> , 2004, 32, 826-827.	3.4	20
84	Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3. <i>Gene Expression Patterns</i> , 2003, 3, 767-776.	0.8	29
85	HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. <i>Leukemia</i> , 2002, 16, 1791-1798.	7.2	177
86	HERG K ⁺ Channels and α 2 β 1 Integrins Interact through the Assembly of a Macromolecular Complex. <i>Annals of the New York Academy of Sciences</i> , 2002, 973, 559-561.	3.8	29
87	HERG K ⁺ Channels Activation during α 2 β 1 Integrin-mediated Adhesion to Fibronectin Induces an Up-regulation of α 5 β 3 Integrin in the Preosteoclastic Leukemia Cell Line FLG 29.1. <i>Journal of Biological Chemistry</i> , 2001, 276, 4923-4931.	3.4	83
88	Relationships between hepatic melanogenesis and respiratory conditions in the newt, <i>Triturus carnifex</i> . <i>The Journal of Experimental Zoology</i> , 2000, 287, 120-127.	1.4	23